top of page
Search

C.H. Robinson

  • Writer: Abacus Research
    Abacus Research
  • 5 minutes ago
  • 1 min read

CHRW has been going through significant change, They are retaking market share.

The new CEO has transformed the company by bringing in a lean / AI, that has helped CHRW to grow earnings despite struggling topline.


  • Even without any help from a cyclical recovery, we expect EPS growth for the next three years to average ~19%.

  • Demand environment highly unlikely to get worse without a severe recession, hence any cyclical upside mostly a free option.

  • We are interested in CHRW because we believe it can take share and because has shown high operating leverage with incremental margins of ~100%.


Potential Upside:     $212 (+32%)

Sensible Downside: $127(-20%)


 
 
 

Recent Posts

See All
Brookfield (BN):

We initially wrote up BN in Jan 2024, it has increased 70%, so why mention it again? Firstly, we think the fundamentals are as good now as they were 2 yrs ago, with a >15% IRR on offer. BN is not a we

 
 
 
Figure (FIGR)

We believe Figure is highly disruptive. If tokenisation of real-world assets is a theme for the next decade, FIGR could be at the centre of it. Figure has found a real-world use for blockchain, provin

 
 
 

Comments

bottom of page